News | September 18, 2015

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children Late-Breaking Data Show 3.5 mg/kg Twice-Monthly Dosing Increased Mean Peak IGF-I SDS and Stabilized 12 to 18 Month Mean Height Velocity While Maintaining Safety...

News | September 17, 2015

Dimension Therapeutics Announces FDA Fast Track Designation for Lead Candidate DTX101 in Patients with Hemophilia B CAMBRIDGE, MASS, September 17, 2015 – Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading gene therapy platform company focused on...

News | September 16, 2015

September 16, 2015 Intarcia Presents Results from Two Successful Phase 3 Trials for ITCA 650, Its Investigational Therapy in Type 2 Diabetes, at 51st EASD Both Phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) met the primary and secondary clinical endpoints, with...

News | September 21, 2015

Waltham, MA  |  Sep 21, 2015 Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline Multiple Clinical Programs for Switch Control Kinase Inhibitor Drug Candidates to Reach Key Milestones in Next 12 months Deciphera...

News | September 21, 2015

Sharp HealthCare Selects QPID Health for PQRS Compliance Leading California health system to use QPID Health’s technology to streamline mandated quality reporting and ensure reports are consistent with high standards of care Boston – September 21, 2015 – QPID Health,...
in mattis at libero ante. ipsum efficitur. elit. tempus